Overview

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Status:
Completed
Trial end date:
2000-12-01
Target enrollment:
Participant gender:
Summary
Patients with superficial transitional cell carcinoma of the bladder will be treated with intravesical suramin in a phase I dose escalating study. The toxicity of suramin administered in this fashion will be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Suramin